Compare ETV & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Current Price
| Metric | ETV | NUVB |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.1B |
| IPO Year | 2005 | 2020 |
| Metric | ETV | NUVB |
|---|---|---|
| Price | $15.19 | $4.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 188.5K | ★ 5.1M |
| Earning Date | 01-01-0001 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 71.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,902,000.00 |
| Revenue This Year | N/A | $211.79 |
| Revenue Next Year | N/A | $45.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 698.96 |
| 52 Week Low | $13.13 | $3.36 |
| 52 Week High | $15.49 | $9.75 |
| Indicator | ETV | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 53.60 | 29.49 |
| Support Level | $14.26 | $4.10 |
| Resistance Level | $15.40 | $5.16 |
| Average True Range (ATR) | 0.21 | 0.24 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 61.51 | 20.80 |
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.